| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.9 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |